/ CompletedNot Applicable 吸入用布地奈德混悬液随机、开放、两制剂、交叉设计在中国健康受试者中的生物等效性正式试验
[Translation] A randomized, open-label, two-dose, crossover design formal bioequivalence study of budesonide suspension for inhalation in Chinese healthy subjects
以山东禾琦制药有限公司的吸入用布地奈德混悬液为受试制剂;并以AstraZeneca Pty Ltd持证的吸入用布地奈德混悬液为参比制剂,进行人体相对生物利用度和生物等效性评价。
[Translation] The budesonide suspension for inhalation produced by Shandong Heqi Pharmaceutical Co., Ltd. was used as the test preparation, and the budesonide suspension for inhalation certified by AstraZeneca Pty Ltd was used as the reference preparation to evaluate the relative bioavailability and bioequivalence in humans.
100 Clinical Results associated with Shandong Heqi Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Shandong Heqi Pharmaceutical Co., Ltd.
100 Deals associated with Shandong Heqi Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Shandong Heqi Pharmaceutical Co., Ltd.